{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:46:15Z","timestamp":1792356375632,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clml.2019.04.008","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:04:10Z","timestamp":1556582650000},"page":"e430-e435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation"],"prefix":"10.1016","volume":"19","author":[{"given":"Sarita Rani","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Bhakuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema Malini","family":"Aiyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneh","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparno","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.04.008_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fonc.2017.00287","article-title":"Allograft for myeloma: examining pieces of the jigsaw puzzle","volume":"7","author":"Malek","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2019.04.008_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s12288-019-01077-x","article-title":"Allogeneic hematopoietic stem cell transplantation for myeloma: time for an obituary or not just yet!","author":"Jaiswal","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2019.04.008_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.04.008_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11899-017-0365-2","article-title":"A\u00a0view from the plateau: is there a role for allogeneic stem cell transplantation in the era of highly effective therapies for multiple myeloma?","volume":"12","author":"Green","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2019.04.008_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.bbmt.2018.04.018","article-title":"Long-term results of prophylactic donor lymphocyte infusions for patients with multiple myeloma after allogeneic stem cell transplantation","volume":"24","author":"Groger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.04.008_bib6","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1182\/blood-2006-03-012542","article-title":"CD28-mediated regulation of multiple myeloma cell proliferation and survival","volume":"109","author":"Bahlis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.04.008_bib7","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/blood-2013-10-530964","article-title":"CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma","volume":"123","author":"Murray","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.04.008_bib8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4049\/jimmunol.1100016","article-title":"CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment","volume":"187","author":"Nair","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2019.04.008_bib9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/bloodadvances.2017011601","article-title":"CD86 regulates myeloma cell survival","volume":"1","author":"Gavile","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.04.008_bib10","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1517\/13543784.9.9.2147","article-title":"CTLA4-Ig: a novel immunosuppressive agent","volume":"9","author":"Najafian","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2019.04.008_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.trim.2017.07.004","article-title":"T\u00a0cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia","volume":"43-44","author":"Jaiswal","year":"2017","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.clml.2019.04.008_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-6143.2005.01172.x","article-title":"NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation","volume":"6","author":"Kean","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2019.04.008_bib13","doi-asserted-by":"crossref","first-page":"e83913","DOI":"10.1371\/journal.pone.0083913","article-title":"CD86 is an activation receptor for NK cell cytotoxicity against tumor cells","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.04.008_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbmt.2018.12.836","article-title":"CTLA4Ig primed donor lymphocyte infusion: a novel approach to immunotherapy following haploidentical transplantation for advanced leukemia","volume":"25","author":"Jaiswal","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.04.008_bib15","first-page":"4468","article-title":"CTLA4Ig primed donor lymphocyte infusions (DLI): a novel approach to natural killer cell immunotherapy following haploidentical PBSC transplantation for advanced hematological malignancies","volume":"130","author":"Jaiswal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.04.008_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.04.008_bib17","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.bbmt.2018.06.003","article-title":"Higher CD45RA(+) regulatory T cells in the graft improves outcome in younger patients undergoing T cell\u2013replete haploidentical transplantation: where donor age matters","volume":"24","author":"Jaiswal","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.04.008_bib18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcyt.2016.12.006","volume":"19","author":"Jaiswal","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2019.04.008_bib19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fimmu.2018.00704","article-title":"One-year follow-up of natural killer cell activity in multiple myeloma patients treated with adjuvant lenalidomide therapy","volume":"9","author":"Besson","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2019.04.008_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood\u2013derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.04.008_bib21","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3324\/haematol.2011.056747","article-title":"Highly activated and expanded natural killer cells for multiple myeloma immunotherapy","volume":"97","author":"Garg","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.04.008_bib22","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1182\/blood-2004-10-4113","article-title":"NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect","volume":"105","author":"Nguyen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.04.008_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019302319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:03Z","timestamp":1761870723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019302319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S2152265019302319"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.04.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}